Cargando…

How I treat metastatic melanoma

Tremendous progress in basic and clinical research has completely revolutionised the management of advanced melanoma, and this dramatic development is still ongoing. In this environment, state-of-the-art patient care is a major challenge. We describe how patient-centred medicine is organised in a le...

Descripción completa

Detalles Bibliográficos
Autores principales:	Dummer, Reinhard, Mangana, Joanna, Frauchiger, Anna Lisa, Lang, Claudia, Micaletto, Sara, Barysch, Marjam J.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2019
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6677980/ https://www.ncbi.nlm.nih.gov/pubmed/31423341 http://dx.doi.org/10.1136/esmoopen-2019-000509

Ejemplares similares

A new B-Raf inhibitor combo for advanced melanoma
por: Barysch, Marjam-Jeanette, et al.
Publicado: (2018)

Sarcoid-like reactions in patients receiving modern melanoma treatment
por: Dimitriou, Florentia, et al.
Publicado: (2018)

Frequency, Treatment and Outcome of Immune-Related Toxicities in Patients with Immune-Checkpoint Inhibitors for Advanced Melanoma: Results from an Institutional Database Analysis
por: Dimitriou, Florentia, et al.
Publicado: (2021)

Long-term pegylated interferon-α and its potential in the treatment of melanoma
por: Dummer, Reinhard, et al.
Publicado: (2009)

Hair Depigmentation and Hair Loss in Advanced Melanoma Treated with Combined Immunotherapy and Targeted Therapy
por: DIMITRIOU, Florentia, et al.
Publicado: (2020)

Impact of Covid-19 on the management of patients with metastatic melanoma
por: Welti, Michèle, et al.
Publicado: (2022)

Addendum: Impact of Covid-19 on the management of patients with metastatic melanoma
por: Welti, Michèle, et al.
Publicado: (2023)

Clinical and Molecular Features of Skin Malignancies in Muir-Torre Syndrome
por: Simic, Dario, et al.
Publicado: (2021)

Phase I, open-label study of pasireotide in patients with BRAF-wild type and NRAS-wild type, unresectable and/or metastatic melanoma
por: Dummer, Reinhard, et al.
Publicado: (2018)

Long‐Term Response to Intermittent Binimetinib in Patients with NRAS‐Mutant Melanoma
por: Matter, Alexandra Valeska, et al.
Publicado: (2020)

Sequential somatic mutations upon secondary anti-HER2 treatment resistance in metastatic ERBB2(S310F) mutated extramammary Paget’s disease
por: Nordmann, Thierry M., et al.
Publicado: (2019)

Diffuse Cutaneous Melanosis Associated with Malignant Melanoma
por: Mangana, Joanna, et al.
Publicado: (2015)

Toxicity of combined targeted therapy and concurrent radiotherapy in metastatic melanoma patients: a single-center retrospective analysis
por: Ziegler, Johanna S., et al.
Publicado: (2020)

Analysis of BRAF and NRAS Mutation Status in Advanced Melanoma Patients Treated with Anti-CTLA-4 Antibodies: Association with Overall Survival?
por: Mangana, Joanna, et al.
Publicado: (2015)

Multicenter, real-life experience with checkpoint inhibitors and targeted therapy agents in advanced melanoma patients in Switzerland
por: Mangana, Joanna, et al.
Publicado: (2017)

Cutaneous Adverse Events of Systemic Melanoma Treatments: A Retrospective Single-Center Analysis
por: Kraehenbuehl, Lukas, et al.
Publicado: (2023)

The role of cyclin D1 and Ki‐67 in the development and prognostication of thin melanoma
por: Kaufmann, Corina, et al.
Publicado: (2020)

Keratinocytic Malfunction as a Trigger for the Development of Solar Lentigines
por: Barysch, Marjam Jeanette, et al.
Publicado: (2019)

Melanoma patients with additional primary cancers: a single-center retrospective analysis
por: Dimitriou, Florentia, et al.
Publicado: (2019)

Evolving impact of long-term survival results on metastatic melanoma treatment
por: Michielin, Olivier, et al.
Publicado: (2020)

How I treat brain metastases of melanoma
por: Eroglu, Z., et al.
Publicado: (2022)

Clock-like Mutation Signature May Be Prognostic for Worse Survival Than Signatures of UV Damage in Cutaneous Melanoma
por: Fröhlich, Fabienne, et al.
Publicado: (2023)

A practical guide to the handling and administration of talimogene laherparepvec in Europe
por: Harrington, Kevin J, et al.
Publicado: (2017)

Coexpression of SOX10/CD271 (p75(NTR)) and β-Galactosidase in Large to Giant Congenital Melanocytic Nevi of Pediatric Patients
por: Barysch, Marjam J., et al.
Publicado: (2014)

A Longitudinal Analysis of IDO and PDL1 Expression during Immune- or Targeted Therapy in Advanced Melanoma()
por: Krähenbühl, Lukas, et al.
Publicado: (2018)

Ectopic axillary breast cancer in a male patient
por: Peil, Nils, et al.
Publicado: (2020)

Prediction of Early Response to Immune Checkpoint Inhibition Using FDG-PET/CT in Melanoma Patients
por: Kudura, Ken, et al.
Publicado: (2021)

Treatment reality of patients with BRAF-mutant advanced/metastatic melanoma in Switzerland in the era of choice
por: Mangana, Joanna, et al.
Publicado: (2022)

The role of diabetes in metastatic melanoma patients treated with nivolumab plus relatlimab
por: Mallardo, Domenico, et al.
Publicado: (2023)

How I treat metastatic triple-negative breast cancer
por: Caparica, Rafael, et al.
Publicado: (2019)

How I treat endocrine-dependent metastatic breast cancer
por: Gombos, A., et al.
Publicado: (2023)

Correction: Kudura et al. Prediction of Early Response to Immune Checkpoint Inhibition Using FDG-PET/CT in Melanoma Patients. Cancers 2021, 13, 3830
por: Kudura, Ken, et al.
Publicado: (2022)

Malignancy Rate of Indeterminate Findings on FDG-PET/CT in Cutaneous Melanoma Patients
por: Kudura, Ken, et al.
Publicado: (2021)

Standardized diagnostic algorithm for spitzoid lesions aids clinical decision-making and management: a case series from a Swiss reference center
por: Hilbers, Marie-Luise, et al.
Publicado: (2021)

Addendum: Standardized diagnostic algorithm for spitzoid lesions aids clinical decision-making and management: a case series from a Swiss reference center
por: Hilbers, Marie-Luise, et al.
Publicado: (2022)

Lung Nodules in Melanoma Patients: Morphologic Criteria to Differentiate Non-Metastatic and Metastatic Lesions
por: Stadelmann, Simone Alexandra, et al.
Publicado: (2021)

PET/CT radiomics for prediction of hyperprogression in metastatic melanoma patients treated with immune checkpoint inhibitors
por: Gabryś, H. S., et al.
Publicado: (2022)

How we treat locoregional melanoma
por: Troiani, T., et al.
Publicado: (2021)

Combining talimogene laherparepvec with immunotherapies in melanoma and other solid tumors
por: Dummer, Reinhard, et al.
Publicado: (2017)

Establishing standardized immune phenotyping of metastatic melanoma by digital pathology
por: Sobottka, Bettina, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_7p5o154d4rbjdr3nskcdo2t2gq